Openbookopenbook
Equity
ALLO
+0.0 · +0.00%
USD · NASDAQ

Allogene Therapeutics Inc(ALLO) Stock Analysis | Healthcare

USD --+0.00%
Reward34Low
Risk39Moderate
75%Data
Revenue down 100% YoY
Earnings Deterioration
Market Cap:722.08M
ⓘ
Reward Rating
34
Low
Reward Assessment
75% data coverage
Bottom 5% of stocksView factors
ⓘ
Risk Rating
39
Moderate
Risk Assessment
3 metrics flaggedView details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on ALLO to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
New listing — limited trading history
Fundamental and analyst data are available for ALLO, but momentum and volatility metrics will develop as more trading history accumulates (0 trading sessions so far).
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $9.00.

What is Allogene Therapeutics Inc?

a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases.

ALLO · Verdict

Limited reward · moderate risk

ALLO's standout is volatility; profitability and growth weigh on the picture.

Based on 88% data coverage

ALLO · Verdict

What’s working & what to watch

Strengths 1

  • Volatility80/100

    Top decile vs peers

Watchouts 3

  • Profitability10/100

    -42% return on equity

  • Growth31/100

    Earnings -16.7% CAGR

  • Balance sheet43/100

    Current ratio 7.93

Model-based scoring. For information only — not financial advice.

What is Allogene Therapeutics Inc?

a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 722.08M.

Financial Highlights

Investment Breakdown

Growth
Revenue growth is subdued, limiting near-term earnings expansion.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Risk profile appears balanced versus broad market conditions.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Low (34)

The scoring profile indicates weak reward characteristics across most factors, including valuation and momentum. Risk indicators are moderate, consistent with typical market exposure.

For informational purposes only. Not financial advice.

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

NGNESmall Cap / 723M market cap
Neurogene Inc
Compare
VBIZFSmall Cap / 724M market cap
Viva Biotech Holdings
Compare
OCSSmall Cap / 719M market cap
Oculis Holding AG Ordinary shares
Compare
Company Information
SectorHealthcare
IndustryBiotechnology
Market Cap722.08M
P/E RatioN/A
Dividend YieldN/A
Beta0.466
Insider Activity
12M windowBearish
Shares soldShares bought
0-3months
0
0
3-6months
572,183 shares
$178k
0
6-9months
7215,855 shares
$378k
0
9-12months
136,744 shares
$46k
0
openbook

Stock research for UK and US investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.